Skip to main content

Advertisement

SpringerLink
Log in

Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need?

  • Original paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Knowledge about psychological health of men with prostate cancer is still limited. HRQoL assessment adds value in symptom management by allowing a broader understanding of the impact of symptom management beyond the targeted symptom, on functioning, and on overall QoL. In this paper, the results of the commonly used HRQoL questionnaires in phase III randomized clinical trials of chemotherapy in metastatic castration-resistant prostate cancer has been discussed. An overview about symptom burden, treatments and HRQoL domains, a description of available HRQoL instruments used for patients with metastatic castration-resistant prostate cancer were reported. Finally, the characteristics of most commonly used HRQoL instruments were identified and compared. To provide better empirical justification for the selection of HRQoL instruments, head-to-head comparisons of them within the same studies are needed. Estimating a minimal important difference could be significant when interpreting trial results. The impact of HRQoL scores in clinical practice remains unclear; poor communication of clinical significance of the results and limited training of clinicians are the most important barriers to a widespread use of HRQoL questionnaires.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

EORTC-QLQ-C30:

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30

CaPSURE:

Cancer of the prostate strategic urologic research endeavor

EQ-5D:

Euro-QoL 5D

FACT-G:

Functional Assessment of Cancer Therapy-General

FACT-P:

Functional Assessment of Cancer Therapy-Prostate

HRQoL:

Health-related quality of life

mCRPC:

Metastatic castration-resistant prostate cancer

PC:

Prostate cancer

EORTC-QLQ-PR25:

European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-PR25

QoL:

Quality of life

RCTs:

Randomized controlled trials

SF-36:

Short Form-36

References

  1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581–92.

    Article  PubMed  CAS  Google Scholar 

  2. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.

    Article  PubMed  CAS  Google Scholar 

  3. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.

    Article  PubMed  CAS  Google Scholar 

  4. Marquis P, Arnould B, Acquadro C, Roberts WM. Patient-reported outcomes and health-related quality of life in effectiveness studies: pros and cons. Drug Develop Res. 2006;67:193–201.

    Article  CAS  Google Scholar 

  5. Fossa SD, Aaronson N, Calais da Silva F, Denis L, Newling D, Hosbach G, et al. Quality of life in patients with muscle-infiltrating bladder cancer and hormone-resistant prostatic cancer. Eur Urol. 1989;16:335–9.

    PubMed  CAS  Google Scholar 

  6. Fujimura T, Takahashi S, Kume H, Takeuchi T, Kitamura T, Homma Y. Cancer-related pain and quality of life in prostate cancer patients: assessment using the Functional Assessment of Prostate Cancer Therapy. Int J Urol. 2009;16:522–5.

    Article  PubMed  Google Scholar 

  7. Sandblom G, Carlsson P, Sennfalt K, Varenhorst E. A population-based study of pain and quality of life during the year before death in men with prostate cancer. Br J Cancer. 2004;90(6):1163–8.

    Article  PubMed  CAS  Google Scholar 

  8. Litwin MS, Lubeck DP, Stoddard ML, Pasta DJ, Flanders SC, Hennings JM. Quality of life before death for men with prostate cancer: results from the CaPSURE database. J Urol. 2001;165(3):871–5.

    Article  PubMed  CAS  Google Scholar 

  9. Melmed GY, Kwan L, Reid K, Litwin MS. Quality of life at the end of life: trends in patients with metastatic prostate cancer. Urology. 2002;59(1):103–9.

    Article  PubMed  Google Scholar 

  10. Sullivan PW, Mulani PM, Fishman M, Sleep D. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res. 2007;16:571–5.

    Article  PubMed  Google Scholar 

  11. Bradley C. Feedback on the FDA’s February 2006 draft guidance on Patient Reported Outcome (PRO) measures from a developer of PRO measures. Health Qual Life Outcomes. 2006. doi:10.1186/1477-7525-4-78.

  12. Rosenfeld B, Roth AJ, Ghandi S, Penson D. Differences in health-related quality of life of prostate cancer patients based on stage of cancer. Psycho-oncol. 2004;13(11):800–7.

    Article  Google Scholar 

  13. Prezioso D, Bartoletti R, Cecchi M, Cicalese V, Cunico SC, Damiano R, et al. Quality of life evaluation by the EORTC QLQ-C30 questionnaire in patients treated with hormonal treatment in Italy. A QuABIOS group study. Arch It Urol Androl. 2007;79:99–103.

    Google Scholar 

  14. Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors. Cancer. 2001;92:1451–9.

    Article  PubMed  CAS  Google Scholar 

  15. Balderson N, Towell T. The prevalence and predictors of psychological distress in men with prostate cancer who are seeking support. Br J Health Psychol. 2003;8:125–34.

    Article  PubMed  Google Scholar 

  16. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999;82:263–74.

    Article  PubMed  CAS  Google Scholar 

  17. Zaza C, Baine N. Cancer pain and psychosocial factors: a critical review of the literature. J Pain Symptom Manage. 2002;24:526–42.

    Article  PubMed  Google Scholar 

  18. De Leeuw JR, de Graeff A, Ros WJ, Blijham GH, Hordijk GJ, Winnubst JA. Prediction of depressive symptomatology after treatment of head and neck cancer: the influence of pre-treatment physical and depressive symptoms, coping, and social support. Head Neck. 2000;22:799–807.

    Article  PubMed  Google Scholar 

  19. Epstein JB, Elad S, Eliav E, Jurevic R, Benoliel R. Orofacial pain in cancer: part II-clinical perspectives and management. J Dental Res. 2007;86:506–18.

    Article  CAS  Google Scholar 

  20. Fischer DJ, Villines D, Kim YO, Epstein JB, Wilkie DJ. Anxiety, depression, and pain: differences by primary cancer. Support Care Cancer. 2009. doi:10.1007/s00520-009-0712-5.

  21. Keefe FJ, Abernethy AP, Campbell LC. Psychological approaches to understanding and treating disease-related pain. Annu Rev Psychol. 2005;56:601–30.

    Article  PubMed  Google Scholar 

  22. Wahl AK, Rustoen T, Rokne B, Lerdal A, Knudsen O, Miaskowski C, et al. The complexity of the relationship between chronic pain and quality of life: a study of the general Norwegian population. Qual Life Res. 2009;18:971–80.

    Article  PubMed  Google Scholar 

  23. Cleeland CS. Symptom burden: multiple symptoms and their impact as patient-reported outcomes. J Natl Cancer Inst Mono. 2007;37:16–21.

    Article  Google Scholar 

  24. U.S. Department of Health and Human Services FDA. Guidance for industry: patient-reported outcome measures: use in medical product development to support labelling claims: draft guidance. Health Qual Life Outcomes. 2006. doi:10.1186/1477-7525-4-79.

  25. Cella D, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.

    PubMed  CAS  Google Scholar 

  26. Osoba D, Zee B, Pater J, Warr D, Kaizer D, Latreille J. Psychometric properties and responsiveness of the EORTC Quality of life questionnaire (QLQ-C30) in patients with breast, ovarian and lung cancer. Qual Life Res. 1994;5:555–67.

    Google Scholar 

  27. Brazier JE, Harper R, Jones NMB, O’Cathain A, Thomas KJ, Usherwood T, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. Br Med J. 1992;305:160–4.

    Article  CAS  Google Scholar 

  28. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. J Clin Oncol. 1984;2:472–83.

    PubMed  CAS  Google Scholar 

  29. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337–43.

    Article  PubMed  CAS  Google Scholar 

  30. Esper P. Measuring quality of life in men with prostate cancer using the Functional Assessment of Cancer Therapy-prostate instrument. Urology. 1997;50:920–8.

    Article  PubMed  CAS  Google Scholar 

  31. van Andel G, Bottomley A, Fossa SD, Efficace F, Coens C, Guerif S, et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur J Cancer. 2008;44:2418–24.

    Article  PubMed  Google Scholar 

  32. Litwin MS, Hays RD, Flink A, Ganz PA, Leake B, Brook RH. The UCLA Prostate Cancer Index: development, reliability, and validity of a health-related quality of life measure. Med Care. 1998;36(7):1002–12.

    Article  PubMed  CAS  Google Scholar 

  33. Wei T, Dunn RL, Litwin MS, Sandler HM, Sanda MG. Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology. 2000;56:899–905.

    Article  PubMed  CAS  Google Scholar 

  34. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–64.

    PubMed  CAS  Google Scholar 

  35. Osoba D, Tannock IF, Ernst DS, Neville AJ. Health-related quality of life in men with metastatic prostate cancer treated with mitoxantrone and prednisone. J Clin Oncol. 1999;17:1654–63.

    PubMed  CAS  Google Scholar 

  36. Covinsky KE, Wu AW, Landefeld S, Connors AF, Phillips RS, Tsevat J, et al. Health status versus quality of life in older patients does the distinction matter? Am J Med. 1999;106:435–40.

    Article  PubMed  CAS  Google Scholar 

  37. Ferrans CE. Differences in what quality-of-life instruments measure. J Natl Cancer Inst Mono. 2007;37:22–6.

    Article  Google Scholar 

  38. Smith KW, Avid NE, Assmann SF. Distinguishing between quality of life and health status in quality of life research: a meta-analysis. Qual Life Res. 1999;8:447–59.

    Article  PubMed  CAS  Google Scholar 

  39. Kemmler G, Holzner B, Kopp M, Dunser M, Greil R, Hahn E, et al. Multidimensional scaling as a tool for analysing quality of life data. Qual Life Res. 2002;11:223–33.

    Article  PubMed  CAS  Google Scholar 

  40. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D’haese S, et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials–Does HRQOL evaluation in prostate cancer research inform clinical decision making? J Clin Oncol. 2003;21:3502–11.

    Article  PubMed  Google Scholar 

  41. Joly F, Vardy J, Pintilie M, Tannock IF. Quality of life and/or symptom control in randomized clinical trials for patients with advanced cancer. Ann Oncol. 2007;18:1935–42.

    Article  PubMed  CAS  Google Scholar 

  42. Cocks K, King MT, Velikova G, Fayers PM, Brown JM. Quality, interpretation and presentation of European Organisation for Research and Treatment of Cancer quality of life questionnaire core 30 data in randomised controlled trials. Eur J Cancer. 2008;44:1793–8.

    Article  PubMed  Google Scholar 

  43. Guyatt G, Schunemann H. How can quality of life researchers make their work more useful to health workers and their patients? Qual Life Res. 2007;16:1097–105.

    Article  PubMed  Google Scholar 

  44. Cella D, Hahn EA, Dineen K. Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002;11:207–21.

    Article  PubMed  Google Scholar 

  45. Braitman LE. Statistical, clinical, and experimental evidence in randomized controlled trials. Ann Intern Med. 1983;98(3):407–8.

    PubMed  CAS  Google Scholar 

  46. Guyatt G, Osoba D, Wu AW, Wyrwich KW, Norman GR, the Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clinic Proc. 2002; 77:371–83.

    Google Scholar 

  47. De Vet HC, Terwee CB, Ostelo RW, Beckerman H, Knol DL, Bouter LM. Minimal changes in health status questionnaires: distinction between minimally detectable change and minimally important change. Health Qual Life Outcomes. 2006. doi:10/1186/1477-7525-4-54.

  48. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J, et al. Analysis and interpretation of health-related quality-of-life data from clinical trials: basic approach of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer. 2005;41:280–7.

    Article  PubMed  Google Scholar 

  49. Moinpour CM, Donaldson GW, Redman MW. Do general dimensions of quality of life add clinical value to symptom data? J Natl Cancer Inst Mono. 2007;37:31–8.

    Article  Google Scholar 

  50. Moinpour CM, Donaldson GW, Nakamura Y. Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial. Qual Life Res. 2009;18:147–55.

    Article  PubMed  Google Scholar 

  51. Abratt RP, Brune D, Dimopoulos MA, Kliment J, Breza J, Selvaggi FP, et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol. 2004;15:1613–21.

    Article  PubMed  CAS  Google Scholar 

  52. Ernst DS, Tannock IF, Winquist EW, Venner PM, Reyno L, Moore MJ, et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol. 2003;21:3335–42.

    Article  PubMed  CAS  Google Scholar 

  53. Kantoff PW, Halabi S, Conaway M, Picus J, Krishner J, Hars V, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999;17:2506–13.

    PubMed  CAS  Google Scholar 

  54. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, et al. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol. 1999;17:3160–6.

    PubMed  CAS  Google Scholar 

  55. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy-Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009;12:124–9.

    Article  PubMed  Google Scholar 

  56. Sullivan PW, Lawrence WF Jr, Ghushchyan V. A national catalogue of preference-based scores for chronic conditions in the U.S. Med Care. 2005;43(7):736–49.

    Article  PubMed  Google Scholar 

  57. Gotay CC. Assessing cancer-related quality of life across a spectrum of applications. J Natl Cancer Inst Mono. 2004;33:126–33.

    Article  Google Scholar 

  58. Lipscomb J, Donaldson MS, Arora NK, Brown ML, Clauser SB, Potosky AL, et al. Cancer outcomes research. J Natl Cancer Inst Mono. 2004;33:178–97.

    Article  Google Scholar 

  59. Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J Clin Oncol. 2006;24:3178–86.

    Article  PubMed  Google Scholar 

  60. Osoba D. Translating the science of patient-reported outcomes assessment into clinical practice. J Natl Cancer Inst Mono. 2007;37:5–11.

    Article  Google Scholar 

  61. Bennett MI. The Brief Pain Inventory: revealing the effect of cancer pain. Lancet Oncol. 2009;10:1020.

    Article  PubMed  Google Scholar 

  62. Rummans TA, Clark MM, Sloan JA, Frosta MH, Botswick JM, Atherton PJ, et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol. 2006;24:635–42.

    Article  PubMed  Google Scholar 

  63. Cohen S. Social relationships and health. Am Psychol. 2004;59(8):676–84.

    Article  PubMed  Google Scholar 

  64. Sultan S, Fisher DA, Voils CI, Kinney AY, Sandler RS, Provenzale D. Impact of functional support on health-related quality of life in patients with colorectal cancer. Cancer. 2004;101:2737–43.

    Article  PubMed  Google Scholar 

  65. Bottomley A, Jones L. Social support and the cancer patient–a need for clarity. Eur J Cancer Care. 1997;6:72–7.

    Article  CAS  Google Scholar 

  66. Williams P, Barclay L, Schmied V. Defining social support in context: a necessary step in improving research, intervention, and practice. Qual Health Res. 2004;14:942–60.

    Article  PubMed  Google Scholar 

  67. Zaninotto P, Falaschetti E, Sacker A. Age trajectories of quality of life among older adults: results from the English Longitudinal Study of Ageing. Qual Life Res. 2009;18(10):1301–9.

    Article  PubMed  Google Scholar 

  68. Fitzsimmons D, Gilbert J, Howse F, Young T, Arraras JI, Brédart A, et al. A systematic review of the use and validation of health-related quality of life instruments in older cancer patients. Eur J Cancer. 2009;45:19–32.

    Article  PubMed  Google Scholar 

  69. Cella D, Bullinger M, Scott C, Barofsky I. and the Clinical Significance Consensus Meeting Group. Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life. Mayo Clinic Proc. 2002;77:384–92.

    Article  Google Scholar 

  70. Gotay CC, Lipscomb J, Snyder CF. Reflections on findings of the Cancer Outcomes Measurement Working Group: moving to the next phase. J Natl Cancer Inst. 2005;97:1568–74.

    Article  PubMed  Google Scholar 

  71. Ganz PA, Goodwin PJ. Health-related quality of life measurement in symptom management trials. J Natl Cancer Inst Mono. 2007;37:47–52.

    Article  Google Scholar 

  72. Donaldson MS. Taking stock of health-related quality of life measurement in oncology practice in United States. J Natl Cancer Inst Mono. 2004;33:155–67.

    Article  Google Scholar 

  73. Greenhalgh J, Long AF, Flynn R. The use of patient reported outcome measures in routine clinical practice: lack of impact or lack of theory? Soc Sci Med. 2005;60:833–43.

    Article  PubMed  Google Scholar 

  74. Collette L, van Andel G, Bottomley A, Oosterhof GON, Albrecht W, de Reijke TM, et al. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. J Clin Oncol. 2004;22:3877–85.

    Article  PubMed  Google Scholar 

  75. Sadetsky N, Hubbard A, Carroll PR, Satariano W. Predictive value of serial measurements of quality of life on all-cause mortality in prostate cancer patients: data from CaPSURE (cancer of the prostate strategic urologic research endeavour) database. Qual Life Res. 2009;18:1019–27.

    Article  PubMed  Google Scholar 

  76. Quinten C, Coens C, Mauer M, Comte S, Sprangers MAG, Cleeland C, et al. Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol. 2009;10:865–71.

    Article  PubMed  Google Scholar 

  77. Emrich LJ, Priore LR, Murphy GP, Brady MF, the Investigators of the National Prostatic Cancer Project. Prognostic factors in patients with advanced stage prostate cancer. Cancer Res. 1985; 45:5173–9.

    Google Scholar 

  78. Fossa SD, Paus E, Lindegaard M, Newling DW. Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostate cancer undergoing experimental treatment. Br J Urol. 1992;69:175–9.

    Article  PubMed  CAS  Google Scholar 

  79. Fossa SD. Quality of life after palliative radiotherapy in patients with hormone-resistant prostate cancer: single institution experience. Br J Urol. 1994;74:345–51.

    Article  PubMed  CAS  Google Scholar 

  80. Garssen B. Psycho-oncology and cancer: linking psychological factors with cancer development. Ann Oncol. 2002;13:172–5.

    Google Scholar 

  81. Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival: metastatic breast cancer. Ann Oncol. 2000;11:469–74.

    Article  PubMed  CAS  Google Scholar 

  82. Tross S, Herndon J, Korzun A, Kornblith AB, Cella DF, Holland JF, et al. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. J Natl Cancer Inst. 1996;88:661–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, ASL-1 Imperiese, Via G. Borea 56, 18038, Sanremo, Imperia, Italy

    Giuseppe Colloca

  2. Department of Educational Sciences, University of Bologna, Via Filippo Re 6, 40126, Bologna, Italy

    Pasquale Colloca

Authors
  1. Giuseppe Colloca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pasquale Colloca
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Colloca.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Colloca, G., Colloca, P. Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration-resistant prostate cancer: which instrument we need?. Med Oncol 28, 519–527 (2011). https://doi.org/10.1007/s12032-010-9495-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9495-2

Keywords

Search

Navigation